Research
Education
Solutions
Sign In
EN
EN - English
CN - 中文
DE - Deutsch
ES - Español
KR - 한국어
IT - Italiano
FR - Français
PT - Português
TR - Turkish
JA - Japanese
Division of Medical Oncology,
Norris Comprehensive Cancer Center,
Keck School of Medicine,
Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine
Evanthia T. Roussos-Torres has not added Biography.
If you are Evanthia T. Roussos-Torres and would like to personalize this page please email our Author Liaison for assistance.
Best Foot Forward: Neoadjuvant Systemic Therapy as Standard of Care in Triple-Negative and HER2-Positive Breast Cancer.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting Mar, 2020 | Pubmed ID: 32315235
Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach.
JCO oncology practice Oct, 2020 | Pubmed ID: 32603252
Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide.
Oncoimmunology 05, 2020 | Pubmed ID: 32923118
Adopting an alternative structure for clinical trials in immunotherapy.
Expert review of anticancer therapy 04, 2021 | Pubmed ID: 33435760
Clocking cancer: the circadian clock as a target in cancer therapy.
Oncogene 05, 2021 | Pubmed ID: 33846572
Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844).
Clinical cancer research : an official journal of the American Association for Cancer Research 11, 2021 | Pubmed ID: 34135021
Lymph Node Immune Profiles as Predictive Biomarkers for Immune Checkpoint Inhibitor Response.
Frontiers in molecular biosciences , 2021 | Pubmed ID: 34141724
Evaluating the impact of age on immune checkpoint therapy biomarkers.
Cell reports 08, 2021 | Pubmed ID: 34433020
Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody-drug conjugates and bispecific antibodies.
Breast cancer research and treatment Jan, 2022 | Pubmed ID: 34716871
Entinostat Decreases Immune Suppression to Promote Antitumor Responses in a HER2+ Breast Tumor Microenvironment.
Cancer immunology research 05, 2022 | Pubmed ID: 35201318
Neurotransmitter signaling: a new frontier in colorectal cancer biology and treatment.
Oncogene 10, 2022 | Pubmed ID: 36182970
University of Southern California
Serena L. Cornelius1,2,
Megan M. Colonnetta2,3,4,5,
Katherine E. Lake1,2,
Clayton A. Smith1,2,
Yu-An Zhang1,2,
Evanthia T. Roussos-Torres6,
Sangeetha M. Reddy1,2,
Elizabeth H. Chen2,3,4,5,
Isaac S. Chan1,2,3,4
1Department of Internal Medicine, Division of Hematology and Oncology, University of Texas Southwestern Medical Center,
2Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center,
3Department of Molecular Biology, University of Texas Southwestern Medical Center,
4Hamon Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center,
5Department of Cell Biology, University of Texas Southwestern Medical Center,
6Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California
Privacy
Terms of Use
Policies
Contact Us
Recommend to library
JoVE NEWSLETTERS
JoVE Journal
Methods Collections
JoVE Encyclopedia of Experiments
Archive
JoVE Core
JoVE Business
JoVE Science Education
JoVE Lab Manual
Faculty Resource Center
Authors
Librarians
Access
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved